Cardiovascular disease in non-classic Pompe disease: A systematic review

H.A. van Kooten\textsuperscript{a}, C.H.A. Roelen\textsuperscript{a}, E. Brusse\textsuperscript{a}, N.A.M.E. van der Beek\textsuperscript{a}, M. Michels\textsuperscript{b}, A.T. van der Ploeg\textsuperscript{c}, M.A.E.M. Wagenmakers\textsuperscript{d}, P.A. van Doorn\textsuperscript{a,*}

\textsuperscript{a}Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands
\textsuperscript{b}Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands
\textsuperscript{c}Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam, the Netherlands
\textsuperscript{d}Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center Rotterdam, the Netherlands

Received 14 May 2020; received in revised form 22 October 2020; accepted 23 October 2020

Abstract

Pompe disease is a rare inherited metabolic and neuromuscular disorder, presenting as a spectrum, with the classic infantile form on one end and the more slowly progressive non-classic form on the other end. While being a hallmark in classic infantile Pompe disease, cardiac involvement in non-classic Pompe disease seems rare. Vascular abnormalities, such as aneurysms and arterial dolichoectasia, likely caused by glycogen accumulation in arterial walls, have been reported in non-classic Pompe patients. With this first systematic review on cardiovascular disease in non-classic Pompe disease, we aim to gain insight in the prevalence and etiology of cardiovascular disease in these patients. Forty-eight studies (eight case-control studies, 15 cohort studies and 25 case reports/series) were included. Fourteen studies reported cardiac findings, 25 studies described vascular findings, and nine studies reported both cardiac and vascular findings. Severe cardiac involvement in non-classic Pompe disease patients has rarely been reported, particularly in adult-onset patients carrying the common IVS1 mutation. There are indications that intracranial dolichoectasia and aneurysms are more prevalent in non-classic Pompe patients compared to the general population. To further investigate the prevalence of cardiovascular disease in non-classic Pompe patients, larger case-control studies that also study established cardiovascular risk factors should be conducted.

© 2020 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: Pompe disease; Cardiac involvement; Vascular abnormalities; Cardiovascular risk factors.

1. Introduction

Pompe disease is an inherited metabolic and neuromuscular disorder. Mutations in the GAA gene lead to deficiency of the enzyme acid α-glucosidase, causing lysosomal glycogen accumulation. This ultimately leads to cell destruction, mainly causing progressive impairment of muscle function [1]. Patients with the classic infantile form of Pompe disease have (virtually) no acid a-glucosidase activity, causing generalized hypotonia, severe hypertrophic cardiomyopathy and respiratory failure. Without treatment, these infants die within the first year of life [2]. In non-classic or late on set Pompe disease, residual activity of acid α-glucosidase causes a more slowly progressive phenotype, with limb-girdle myopathy and respiratory muscle weakness as the main symptoms [3]. While severe cardiomyopathy is a hallmark of classic infantile Pompe disease, cardiac involvement in non-classic Pompe disease seems rare [4,5]. Vascular abnormalities such as aneurysms, (vertebrobasilar) dolichoectasia and arterial dissections have been reported in several cases of non-classic Pompe patients [4–8]. Pathology studies have shown that glycogen may accumulate in endothelial cells and smooth muscle cells within the media of arterial walls of Pompe patients, and it is hypothesized that these changes cause weakness of the arterial wall [9–13]. Moreover, we have previously found increased aortic stiffness in adults with Pompe disease. This is an independent risk

* Corresponding author.
E-mail address: p.a.vandoorn@erasusmc.nl (P.A. van Doorn).

https://doi.org/10.1016/j.nmd.2020.10.009
0960-8966 © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
factor for cardiovascular disease and stresses the importance of appropriate cardiovascular care in these patients [14,15]. However, cardiovascular disease is also very prevalent among the general population, and literature on cardiovascular disease in non-classic Pompe disease is very diverse, mainly consisting of case reports and relatively small case series [16]. Therefore at present, it is not clear if patients with non-classic Pompe have a higher cardiovascular risk than the general aging population and, if this is the case, if this is caused by Pompe disease itself or a higher prevalence of established cardiovascular risk factors such as physical inactivity or obesity. To our knowledge, this is the first systematic review on cardiovascular disease in non-classic Pompe disease patients. By analyzing the current literature, we aim to gain insight in the prevalence and etiology of cardiovascular disease in non-classic Pompe disease. This potentially could help to formulate diagnostic and monitoring strategies, and improve cardiovascular care to prevent serious morbidity and even mortality in patients with non-classic Pompe disease.

2. Methods

2.1. Search strategy

A systematic search in Embase, Medline Epub (Ovid), Cochrane Central, Web of Science and Google Scholar was performed on February 14, 2018 and updated in November 2019. Keywords of ‘Pompe disease’ (glycogen storage disease type 2, acid maltase deficiency, glycogenosis) and different types of ‘cardiovascular disease’ (cardiac disease, cerebrovascular disease, aneurysm, arrhythmia, stroke) were combined. Studies in animals, conference abstracts and editorials were excluded. The full search strategy is summarized in Appendix 1.

2.2. Selection strategy

All retrieved publications were reviewed by two independent reviewers (HVK and CR). There were two stages in this process. First, the title and abstract of all retrieved publications were screened by both reviewers. Publications primarily reporting on cardiovascular disease were selected, studies on classic or atypical infantile Pompe disease (these patients were not the focus of our study) were excluded. In the second stage, full-text articles of the included publications were assessed for eligibility. Studies with no full-text available or full-text only in languages other than English were excluded. Review articles were excluded as well. At both stages, discrepancies in selection of publications between the two reviewers were discussed, to reach consensus on in/exclusion. Remaining uncertainties regarding inclusion were discussed with a third reviewer (PD). The remaining publications included after this stage were reviewed in detail. In addition, the reference lists of excluded review articles and all included publications were searched for additional studies not found by our search strategy.

2.3. Data extraction

For the included studies, data was extracted using a data extraction table. Extraction was conducted by both reviewers and again compared, to ensure reliability and accuracy of the extracted information. Based on the clinic(s) where the study was conducted, the possibility that different studies reported on the same cohort of patients was evaluated. We assessed the certainty of the Pompe disease diagnosis based on the techniques mentioned in the article: 1. definite Pompe disease (genetically confirmed), 2. probable Pompe disease (acid α-glucosidase deficiency, combined with muscle biopsy abnormalities, or specific Pompe disease symptoms in combination with treatment with ERT) or 3. possible Pompe disease (no diagnostics mentioned or only results of a muscle biopsy typical for Pompe disease reported).

2.4. Synthesis of results

Due to heterogeneity of the included studies, a meta-analysis could not be performed. Aiming to overcome the variability and extensiveness of the information retrieved, study outcomes were grouped into two key themes: cardiac findings and vascular findings. Cardiac findings were further grouped into electrocardiogram (ECG) findings and findings on transthoracic echocardiogram (TTE) or other imaging. Findings and events related to vascular abnormalities/disease were further divided into six main categories: 1. ectasia/dilatation, 2. aneurysms, 3. stroke, 4. white matter lesions (WML) and microhemorrhages (MH), 5. pathology findings (PA) and 6. other. Vascular ectasias/dilatations and aneurysms were further grouped based on their location: anterior cerebral circulation (anterior or middle cerebral artery), vertebrobasilar circulation (vertebral or basilar artery), carotid arteries (common or internal carotid artery), aorta, iliac artery, renal artery.

3. Results

3.1. Study selection

Our literature search retrieved 1482 studies. Through reference lists of included studies, three additional studies were included. Forty-one studies fulfilled our criteria and were included in the review (Fig. 1). Seven additional studies were included from the updated search in November 2019.

3.2. Characteristics of included studies

The characteristics of the included studies (n=48) are summarized in Table 1. Most studies were case reports or case series (n=25), eight case control studies and 15 cohort studies were included. Multiple case-control and cohort studies reported on patients from the same cohorts. We considered the diagnosis of Pompe disease definite (genetically confirmed) in 32 studies. Twelve studies were classified as probable Pompe disease (no DNA data
Table 1
Study characteristics.

| Author (year) | Patients (N) | Pompe diagnosis* | Diagnostic modality/modalities | Outcome† |
|---------------|-------------|-----------------|--------------------------------|---------|
| **Case-control studies** | | | | |
| Nemes (2007)* | 17 | 1 | BP, TTE | C, V |
| Wens (2014)* | 84 | 1 | BP, cervical US, PWV | V |
| Fayssoil (2014) | 10 | 3 | ECG, TTE | C |
| Hensel (2015)* | 10 | 1 | brain MRI/MRA, TCD | V |
| Morris (2015) | 12 | 3 | cardiac MRI, ECG, holter ECG, TTE | C |
| Boentert (2016) | 17 | 1 | CMR | C |
| Hensel (2018)* | 20 | 1 | brain CT/CTA/MRI/MRA | V |
| Schneider (2019)* | 19 | 1 | brain MRI | V |
| **Cohort studies** | | | | |
| Müller-Felber (2007)* | 38 | 1 | ECG, holter ECG, TTE | C, V |
| Soliman (2008)* | 46 | 1 | ECG, TTE | C |
| Van der Beek (2008)* | 68 | 1 | ECG, TTE | C |
| Sacconi (2010)* | 6 | 2 | brain MRI | V |
| El-Gharbawy (2011) | 40 | 1 | chest CT/CTA/MRA, CXR, TTE | V |
| Forsha (2011)* | 87 | 1 | ECG, TTE | C |
| Sacconi (2014) | 4 | 1 | ECG, holter ECG, TTE | C |
| Schüller (2012)* | 44 | 1 | ECG, TTE | C, V |
| Montagnese (2016)* | 21 | 1 | brain CT/CTA | V |
| Van Capelle (2016)* | 31 | 1 | ECG, TTE | C |
| Garibaldi (2017)* | 5 | 2 | brain MRI | V |
| Pichiecchio (2017) | 18 | 1 | brain CT/CTA/MRI/MRA | V |
| Herbert (2018)* | 83 | 1 | CXR, ECG, TTE | C |
| Musumeci (2019)* | 21 | 1 | brain MRI/MRA, NPP | V |
| Alandy-Dy (2019) | 18 | 1 | NM | C, V |
| **Case reports/case series** | | | | |
| Francesconi (1982) | 1 | 2 | ECG, TTE | C |
| Miyamoto (1985) | 2 | 2 | brain CT, PA | V |
| Braunsdorf (1987) | 1 | 3 | brain CT/MRI | V |
| Makos (1987) | 3 | 2 | brain CTA, PA | V |
| Matsuoka (1988) | 1 | 2 | PA | V |
| Kretzschmar (1990) | 1 | 2 | brain CT/MRI, ECG, PA | C, V |
| Anneser (2005) | 1 | 1 | brain CTA/MRI/MRA | V |
| Bretschneider (2008) | 1 | 1 | brain MRI/MRA | V |
| Laforêt (2008) | 3 | 1 | brain CT/CTA/MRI/MRA, cervical US | V |
| Refai (2008) | 1 | 2 | brain CT/MRI, DSA | V |
| Renard (2010) | 1 | 1 | brain MRI/MRA | V |
| Fernández (2012) | 1 | 1 | ECG, TTE | C |
| Goebel (2013) | 1 | 3 | aorta CT, brain CT, PA | C, V |
| Céron-Rodríguez (2014) | 1 | 1 | ECG, TTE | C |
| Peric (2014) | 1 | 1 | abdominal US, brain CT/CTA, ECG, TTE | V |
| Quenardelle (2014) | 1 | 1 | brain MRI/MRA, ECG, PA, TTE | V |
| Sandhu (2014) | 1 | 2 | brain CT/MRI/MRA | V |
| Huded (2016) | 2 | 2 | brain CT/MRI, DSA | V |
| Zhang (2016) | 1 | 1 | brain CT, ECG, TTE | C, V |
| Kim (2017) | 1 | 1 | ECG, TTE | C |
| Malhotra (2017) | 1 | 2 | brain CT/CTA/MRI | V |
| Mori (2017) | 1 | 2 | cardiac MRI, PA, TTE | C, V |
| Walczak-Galezewska (2017) | 1 | 2 | brain MRI, CMR, ECG, TTE | C |
| Hossain (2018) | 1 | 1 | brain CT/MRI, TTE | C, V |
| Pappa (2018) | 1 | 1 | abdominal CT, brain CT/CTA/MRA, renal arteriography | V |

* 1: definite Pompe disease (genetically confirmed); 2: probable Pompe disease (enzyme activity combined with muscle biopsy abnormalities or enzyme activity only or specific Pompe symptoms and treatment with ERT); 3: possible Pompe disease (only muscle biopsy abnormalities or no diagnostics mentioned).
† C: cardiac; V: vascular; a, b, c, d: studies that (likely) included patients from the same cohort; BP: blood pressure measurement; CMR: cardiovascular magnetic resonance; CT: computerized tomography; CTA: computed tomography angiography; CXR: chest X-ray; ECG: electrocardiogram; MRI: magnetic resonance imaging; NM: not mentioned; NPP: neuropsychological profile; PA: pathology; PWV: pulse wave velocity measurement; TCD: transcranial Doppler; TTE: transthoracic echocardiography; US: ultrasound.
mentioned) and in four studies no specific diagnostics or only muscle biopsy abnormalities were mentioned (based on the level of certainty, these studies were classified as possible Pompe disease), all patients were included in our review. Most commonly used diagnostic modalities to investigate cardiovascular disease were: ECG, TTE, magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), computed tomography (CT), computed tomography angiography (CTA) and PA. Fourteen studies reported on cardiac outcomes, 25 studies described vascular outcomes, and nine studies reported on both cardiac and vascular outcomes.

### 3.3. Cardiac findings

The findings of 23 studies reporting on cardiac findings are summarized in Table 2.

#### 3.3.1. Cardiac findings in case-control studies

In Table 2A, outcomes of four small case control studies on cardiac outcomes are summarized [18–21]. Two studies performed ECGs, one of these studies reported no abnormalities in 12 Pompe patients [18]. The other study reported one patient with a short PR-interval (sPR) and one patient with a right bundle branch block (RBBB), among 10 Pompe disease patients, but ECG findings in controls were not reported [19]. In two other studies ECGs were not reported [20,21]. In all four studies echocardiography and/or cardiac MRI was performed. Two studies, with in total 22 patients and 194 controls, did not find significant differences in structural or functional cardiac features between patients and controls [18,19]. One study reported a larger mean diastolic aortic diameter (measured with TTE) in 17 Pompe patients compared to 17 controls [20]. One study reported significant differences in left ventricular global radial strain (LV-GRS) and left ventricular global circumferential strain (LV-GCS) (both measures of cardiac deformation), measured with MRI between 17 patients and 18 controls, but findings were within the normal range in both groups [21].

#### 3.3.2. Cardiac findings in cohort studies

Nine cohort studies reporting on cardiac findings are summarized in Table 2B. Eight cohort studies (describing 528 cases in total) performed ECGs. Multiple studies
Table 2
Findings of studies focusing on cardiac outcomes.

### A. Case-control studies

| Reference (year) | Patients/controls (N) | Pompe disease onset (N) | Age (years) | Outcomes significantly different between patients and controls |
|------------------|-----------------------|-------------------------|-------------|-------------------------------------------------------------|
|                  |                       | Childhood | Adult | | |
| Fayssois (2014)  | 10/7                  | NR        | NR     | 56.7 (10.2)       | – |
| Morris (2015)    | 12/187                | 0         | 12     | 37.9 (13.4)       | – |
| Boentert (2016)  | 17/18                 | 4         | 13     | 50 (18)           | HC, LV-GCS, LV-GRS |

### B. Cohort studies

| Reference (year) | Pts with abnormality (N) | Pompe disease onset (N) | Age (years) | Findings (N) | ECG | TTE/imaging | CV RF |
|------------------|--------------------------|-------------------------|-------------|--------------|-----|--------------|-------|
|                  |                         | Childhood | Adult | | | | |
| Müller-Felber (2007)† | 8                        | 6          | 32     | NR           | VPC (5), WPWs (3) | – | NR |
| Soliman (2008)‡ | 13                      | 0          | 46     | 48 (12)†     | AF (1), LAHB (1), LBBB (1), RBBB (1), sPR (1) | BVH (1), DDF (9), dEF (1), LVD (1) | HT (11), DM (2) |
| Van der Beek (2008)§ | 6                       | 23         | 45     | 38 (19)§     | AF (1), LBBB (1), LAHB (1), RBBB (1), sPR (1), WPW (1) | BVH (1), dEF (1), LVED (1), VA (1) | S (2), DM (2), HT (1) |
| Forsha (2011)¶ | 40                       | NR         | NR     | 44 (39–52)¶  | IBBB (2), LAE (3), LBBB (1), LVH (10), pQRS (1), pQHT (3), RAE (1), RBBB (1), sPR (8), ST (5), WPW (2) | dEF (6), LVMI (4) | NR |
| Schüller (2012)¶ | 19                       | NR         | NR     | 18–62‡       | RBBB (2), SA (7), SSS (1) WPWs (3) | LVH (6) | – |
| Sacconi (2014) | 4                        | 0          | 131    | 35–55†       | AVB (4), pQHT (1), ST (1) | – | – |
| Van Capelle (2016)¶ | 6                       | 31         | 0      | 0.1–17.1†    | sPR (3) | HCM (2), VA (3) | NR |
| Herbert (2018)¶ | 29                       | NR         | NR     | 0.5–78¶      | AVB (1), MA (8), RBBB (1), SVT (2) | LAE (4), LVH (14), VD (18) | HT, DM, HL (N?) |
| Aandy-dy (2019)¶ | 2                       | 5          | 13     | 53.7 (14)¶   | NP | – | CM (3) | NR |

### C. Case reports/case series

| Reference (year) | Pompe disease onset (N) | Age (years) | Findings |
|------------------|-------------------------|-------------|----------|
|                  |                         | Childhood | Adult | ECG | TTE/imaging | PA | CV RF |
| Francesconi (1982) | 1                       | 1          | 30     | AVB, PES | – | – | NR |
| Kretzschmar (1990) | 1                       | 1          | 40     | RBBB | NP | MA | NR |
| Fernández (2012) | 1                       | 1          | 12     | sPR | – | – | NR |
| Goeber (2013) | 1                       | 1          | 48     | – | LVH, LVD | – | NR |
| Céron-Rodríguez (2014) | 1              | 1          | 9      | VRD | BVH, PH, RAE | – | NR |
| Zhang (2016) | 1                       | 1          | 28     | – | VA | – | NR |
| Kim (2017) | 1                       | 1          | 5      | WPWs | HCM, LVOT | – | NR |
| Mori (2017) | 1                       | 1          | 33     | NP | DCM, dEF | GS | NR |
| Walczak-Galezewska (2017) | 1       | 1          | 54     | – | dEF, HMI | – | HC |
| Hossain (2018) | 1                       | 1          | 59     | NP | LAE, LVH | – | HT |

* mean (SD).
† median (interquartile range).
‡ range: N: number of patients; a,b,c studies that (likely) included patients from the same cohort; = no abnormalities; NP: not performed; NR: not reported.
AF: atrial fibrillation; AVB: atrioventricular block; BVH: biventricular hypertrophy; CM: cardiomyopathy; DCM: dilated cardiomyopathy; DDF: diastolic dysfunction; dEF: decreased ejection fraction; DM: diabetes mellitus; ECG: electrocardiogram; GS: lysosomal glycogen storage and myocyte vacuolization; HC: hypercholesterolemia; HCM: hypertrophic cardiomyopathy; HL: hyperlipidemia; HMI: heart muscle infiltration; HT: hypertension; IBBB: incomplete bundle branch block; LAE: left atrium enlargement; LAHB: left anterior hemi block; LBBB: left bundle branch block; LV: left ventricular hypertrophy; LVMI: left ventricular mass; LVOT: left ventricular outflow tract obstruction; MA: minor abnormalities (unspecified); PA: pathology; PES: pre-excitation syndrome; PH: pulmonary hypertension; pQRS: prolonged QRS-interval; pQHT: prolonged QT-interval; RAE: right atrium enlargement; RBBB: right bundle branch block; S: smoking; SA: sinusarrhythmia; SP: short PR-interval; SSS: sick sinus syndrome; ST: simustachycardia; SVT: supraventricular tachycardia; TTE: transthoracic echocardiography; VA: various valve abnormalities; VD: valvular dysfunction; VPC: ventricular premature complexes; VRD: ventricular repolarization disorder; WPW: Wolff-Parkinson-White pattern; WPWs: Wolff–Parkinson–White syndrome.
reported on the same cohorts of patients [22–30]. Sixteen
different ECG findings were described. Most commonly
reported findings were sPR, RBBB and Wolf-Parkinson-White
syndrome (WPWs). The prevalence of these findings varied
between different studies: sPR was reported in 1.5–9.7% of
patients, RBBB in 1.2–6.3% of patients and WPWs in
2.3–7.9% of patients. Signs of left ventricular hypertrophy
(LVH) on ECG were reported in 10/87 (11.5%) of patients
in one study, only one of these patients showed elevated left
ventricular mass (LVMI) on echocardiography [28].

Eight cohort studies performed cardiac imaging
and/or function tests using TTE, one study did not
report what type of diagnostic modality was used [31].
Most commonly reported findings were various valvular
abnormalities/dysfunction (VA/VD), LVH and decreased
ejection fraction (dEF). The prevalence of these conditions
in different studies was 1.5–21.7% for VA/VD, 13.6–16.7% for
LVH and 1.5–6.9% for dEF. One study reported two
children with a hypertrophic cardiomyopathy (HCM), both
patients did not carry the common IVS1 mutation and had a
very early onset of Pompe disease symptoms (before the age
of 1) [25]. One study reported three adults (aged 22, 40 and
42 years) with cardiomyopathy (unspecified) which improved
with ERT, of whom one had a childhood onset of Pompe
disease and did not carry the common IVS1 mutation [31].

3.3.3. Cardiac findings in case reports and case series

As summarized in Table 2C, 10 case reports described
cardiac findings. Six different ECG findings were described
in five individual patients (age 5–40 years). One study
reported WPWs and HCM with left ventricular outflow tract
obstruction (LVOT) in a five-year-old girl, which improved
after start of ERT at age 15 [32].

Abnormalities on TTE or other imaging were described in
seven patients, with LVH and dEF being the most common.
Hypertrophic cardiomyopathy was described only in the above
mentioned five-year old girl. One 33-year-old woman with
a dilated cardiomyopathy (DCM) and myocardial glycogen
accumulation (GA) with vacuolization was reported, ERT was
not started because of severe and irreversible cardiac muscle
damage [33]. One other study describing pathology findings
reported that the heart was “minimally affected”, without
further specification of these abnormalities [9].

3.4. Vascular findings

In Table 3, 34 studies reporting on vascular findings are
summarized.

3.4.1. Vascular findings in case-control studies

As shown in Table 3A, five case control studies focused
on vascular outcomes. Two studies, reporting on the same
cohort of patients, reported increased aortic stiffness
in Pompe patients, using aortic stiffness index (ASI) and carotid-
femoral pulse wave velocity measurement (cPWV) as
non-invasive methods to measure aortic stiffness [14,20]. These
studies also reported higher mean arterial pressure (MAP) and
smaller carotid artery diameter in Pompe patients compared
to controls.

One study reported a larger diameter of the carotid,
cerebral anterior circulation and vertebrobasilar circulation
arteries in 10 Pompe patients compared to controls [34]. Also
carotid and vertebral artery mean flow velocity (MFV) and
carotid and vertebrobasilar cerebral blood flow (CBF) were
higher in Pompe patients compared to controls in this study.
These 10 patients plus 10 new patients were described in
another study, reporting abnormal length, volume and height
of the bifurcation of the basilar artery in patients compared
to 40 controls [35]. During five year follow up, one patient
experienced an intracerebral hemorrhage (ICH). White matter
lesions were also reported in this study, but the prevalence
of WML did not differ between patients and controls. This
cohort of patients was studied again using cerebral MRI, this
study showed no significant difference in Fazekas score and
WML volume between Pompe patients and controls matched
for age, sex and number of cerebrovascular risk factors [36].

3.4.2. Vascular findings in cohort studies

Eight cohort studies reported on vascular findings, as
shown in Table 3B. All studies performed (vascular) imaging
and reported on a total of 193 cases. However, the number
of individual patients is probably lower, since several
studies reported on the same cohorts of patients [27,30,37–
40]. Most commonly reported findings or events were
dolicho)ectasias, aneurysms, strokes and WML. Six studies
reported (dolicho)ectasias of the vertebrobasilar circulation
(VBD), the carotid arteries (CAE) and the anterior circulation
(ACD). The prevalence of these findings varied between
different studies: VBD was reported in 2–72% of patients,
CAE in 39–50% of patients and ACD in 28% of patients.
One study reported no significant changes in MRA findings
and no major vascular events during 10-year follow up
of five patients with VBD and CAE [38]. Four studies
reported aneurysms; anterior circulation aneurysms (ACA)
were reported in 2–14% of patients, aortic aneurysms (AA)
were reported in 2–10% of patients and vertebrobasilar
aneurysms (VBA) were reported in 3–6% of patients. Strokes
were reported in five studies, with ischemic stroke (IS)
occurring in 3–10% of patients. White matter lesions were
commonly reported, with a prevalence ranging from 62% to
100% of patients.

3.4.3. Vascular findings in case reports and case series

In Table 3C, 20 case reports/series reporting on vascular
findings are summarized. Vascular abnormalities or events in
25 individual patients were reported. In total, 19 cases of
(dolicho)ectasia at various locations (vertebrobasilar (n = 8),
diffuse cerebral (n = 5), carotid arteries (n = 3), anterior
circulation (n = 1), renal artery (n = 1) and iliac artery (n = 1))
were reported. Ages of the reported patients ranged from 16
to 68 years. Ten aneurysms (located at the vertebrobasilar
circulation (n = 7), anterior circulation (n = 2) and aorta
(n = 1)) were described in patients aged 16–59 years. In
five patients rupture of an intracerebral aneurysm caused
### A. Case-control studies

| Reference (year) | Patients/ controls (N) | Pompe disease onset (N) | Age (years) | Outcomes significantly different between patients and controls |
|------------------|------------------------|-------------------------|-------------|---------------------------------------------------------------|
| Nemes (2007)⁴ [20] | 17/17                  | Child 17                | 44 (8)†     | ASI, BML, DAD                                                  |
| Wens (2014)² [14] | 84/179                 | Adult 17                | 54 (42-63)² | ART, CA-D, cPWV, HR, HT, MAP                                  |
| Hensel (2015)³ [34] | 10/20                  | Child 1                  | 44-71†      | BA-CBF, BA-D, CA-CBF, CA-D, CA-MFV, MCA-D, VA-CBF, VA-D, VA-MFV |
| Hensel (2018)⁴ [35] | 20/40                  | Adult 3                 | 53.7 (14.6)⁺| BA-D, BA-H, BA-L, BA-V, SUCA-OA                               |
| Schneider (2019)³ [36] | 19/38                  | Child 3                 | 54.4 (19.82)⁺|                                                           |

### B. Cohort studies

| Reference (year) | Pts with abnormality (N) | Pompe disease onset (N) | Age (years) | Findings/events related to vascular abnormalities (N) |
|------------------|--------------------------|-------------------------|-------------|-------------------------------------------------------|
| Müller-Felber (2007)⁵ | 1                        | Child 1                 | 28          | IS                                                   |
| Sacconi (2010)⁶ [37] | 4                        | Adult 4                 | 38-69†      | CAE (3), VBD (4)                                     |
| El-Gharbawy (2011)⁵ [83] | 5                       | Child 4                 | 33-64†      | AA (4), VBA (1)                                      |
| Schiller (2012)² [27] | 3                       | Adult 1                 | 30-53†      | VBD (1), AA (1), ACA IS (2)                           |
| Montagone (2016)⁵ [39] | 18                      | Adult 1                 | 50 (15-97)†| VBD (10)                                             |
| Garibaldi (2017)² [38] | 3                       | Adult 3                 | 62-78†      | CAE (2), VBD (3)                                     |
| Pichiecchio (2017)⁶ [63] | 1                       | Adult 2                 | 52.3 (28-76)†| ACD (5), CAE (7), VBD (13)                           |
| Musumeci (2019)² [40] | 21                      | Adult 4                 | 49 (1-4)†   | VBD (11), ACA (3)                                    |
| Alandy-Dy (2019)² [31] | 1                       | Adult 5                 | 53.7 (14-9)⁺| VBA (1)                                              |

### C. Case reports/case series

| Reference (year) | Pompe disease onset (N) | Age (years) | Findings/events related to vascular abnormalities (N) |
|------------------|--------------------------|-------------|-------------------------------------------------------|
| Miyamoto (1985)⁶ [86] | 1                        | Adult 25    | VBA, SAH                                              |
| Braunsdorf (1987)⁶ [87] | NR                      | Adult 34    | CAE (1), VBD (2)                                      |
| Makos (1987)⁶ [10] | 2                        | Adult 1     | VBA (2), IS (1), SAH (2)                              |
| Matsusaka (1988)⁶ [88] | 1                        | Adult 20    | VBA, IS, SAH                                          |
| Kretzschmar (1990)⁶ [9] | 1                       | Adult 40    | MH                                                    |
| Aznar (2005)⁶ [89] | 1                        | Adult 30    | DCD, MH                                               |
| Brettscheider (2008)⁶ [90] | 1                       | Adult 68    | ICH, MH                                               |
| Laforté (2008)⁶ [91] | 2                        | Adult 30-44⁺| DCD (1), VBD (1)                                      |
| Refai (2008)⁶ [55] | 1                        | Adult 19    | VBD                                                   |
| Renard (2010)⁶ [92] | 1                        | Adult 68    | ACD, VBD                                             |
| Goebler (2013)⁶ [94] | 1                        | Adult 48    | VBD, AA                                               |
| Peric (2014)⁶ [96] | 1                        | Adult 50    | ACA, SAH                                              |
| Quendelie (2014)⁶ [97] | 1                       | Adult 52    | CAE, IAD, RAD, VBD                                   |
| Sandhu (2014)⁶ [98] | NR                       | Adult 25    | DCD, VBD                                              |
| Huded (2016)⁶ [99] | 2                        | Adult 40, 43 | DCD (2), IS (2), MH (1)                               |
| Zhang (2016)⁶ [100] | 1                        | Adult 28    | VBA, IS                                               |
| Malhotra (2017)⁶ [101] | 1                       | Adult 40    | IS, IS, NR                                            |
| Mor (2017)⁶ [33] | 1                        | Adult 33    | IS, NR, BA-S                                          |
| Hossain (2018)⁶ [103] | 1                       | Adult 57    | ACA, IS, SAH                                          |
| Pappa (2018)⁶ [104] | 1                        | Adult 38    | ICH, NR, RA-D, VBD                                   |

N: number of patients,⁴⁻⁷ studies that (likely) included patients from the same cohort, d follow up of 5/6 patients of Sacconi (2010), e findings of 17/21 patients were previously reported by Montagnone (2016); * mean (SD); † median (interquartile range); ‡ median (range); ‡‡ mean; AB: arterial abnormalities; AA: aortic aneurysm; ACA: anterior circulation aneurysm; ACD: anterior circulation (dolicho)ectasia/dilatation; AD: aortic dissection; ART: aortic reflexion time; ASI: aortic stiffness index; BA-CBF: basilar artery cerebral blood flow; BA-D: basilar artery diameter; BA-F: basilar artery fenestration; BA-H: height of basilar artery bifurcation; BA-L: basilar artery length; BA-S: basilar artery stenosis; BA-V: basilar artery volume; BMI: body mass index; DM: diabetes mellitus; CA-CBF: carotid artery cerebral blood flow; CA-D: carotid artery diameter; CAE: carotid artery ectasia/dilatation; CA-MFV: carotid artery mean flow velocity; cPWV: carotid-femoral pulse wave velocity; CV RF: cardiovascular risk factors; DAD: diastolic arterial diameter; DDC: diffuse cerebral (dolicho)ectasia/dilatation; DCP: diffuse cerebral pseudo-aneurysm; ENEV: elongated neck vessels; GA: glycogen accumulation in vascular smooth muscle cells; HC: hypercholesterolemia; HT: hypertension; HR: heart rate; IAD: iliac artery dilation; ICD: internal carotid artery dissection; ICH: intracranial hemorrhage; IS: ischemic stroke; Kl: kidney infarct; MAP: mean arterial pressure; MCA-D: mid cerebral artery diameter; MH: microhemorrhages; OB: obesity; PA: pathology; PSSG: punctate subcortical gliosis; RAD: renal artery dilatation; SAH: subarachnoid hemorrhage; SUCA-OA: superior cerebellar artery outlet angle; TIA: transient ischemic attack; VAC: vascular changes in vascular smooth muscle cells; VA-CBF: vertebral artery cerebral blood flow; VA-D: vertebral artery diameter; VA-MFV: vertebral artery mean flow velocity; VBA: vertebrobasilar circulation aneurysm; VBD: vertebrobasilar (dolicho)ectasia/dilatation; WML: white matter lesions.
a subarachnoid hemorrhage (SAH). Ischemic strokes were reported in nine patients (aged 19–59 years), ICH in three patients (aged 25–68 years). Six patients with MH and two patients with WML were reported. Pathology findings were described in six studies; five of these studies reported vacuolar changes and/or glycogen accumulation within smooth muscle cells in the media of the arterial walls, one study reported no abnormalities. Two patients with a kidney infarct (KI) and one patient with a dissection of the internal carotid artery (ICD) were reported.

3.5. Cardiovascular risk factors

Reported cardiovascular risk factors for all studies are summarized in Tables 2 and 3. For case control studies, only risk factors between patients and controls being significantly different are reported in the tables. Non-significantly different cardiovascular risk factors reported in these case-control studies were: hypertension (30–70%), hypercholesterolemia/hyperlipidemia (10–70%), diabetes mellitus (6–20%), obesity (18–40%), and smoking (5–30%). In the cohort studies, hypertension was reported in 22–33%, diabetes in 4–11%, smoking in 19–33%, hypercholesterolemia/hyperlipidemia in 19–24% and obesity in 11–14% of patients.

4. Discussion

To our knowledge, this is the first systematic review on cardiovascular disease in non-classic Pompe disease. It gives a comprehensive overview of the present literature. A large number of studies were included (n=48), reporting on 750 cases in total. However, the exact number of individual patients is difficult to estimate, since several studies reported on the same cohorts of patients. Moreover, we could not determine the level of diagnostic certainty of all patients in the included papers, as in some cases or papers the diagnosis was not genetically confirmed, or the DNA results were not reported. Also, the level of evidence of the studies was variable, a large proportion of the included studies are case reports or case series (n=25) and outcomes and used methodologies vary greatly. It was not possible to perform meta-analysis, but a thorough qualitative analysis was performed.

In case-control studies, no significant differences between patients and controls were reported for ECG findings [18,19]. However, patient numbers were small. In cohort studies, various ECG/conduction abnormalities were described, with sPR, RBBB and WPW pattern/syndrome being the most common. The cause of conduction abnormalities in non-classic Pompe patients may be glycogen accumulation in the myocardium and/or conduction system [11,41]. However, minor ECG findings and conduction abnormalities, like RBBB, have a high prevalence in the general, healthy population as well [42]. Wolff–Parkinson–White syndrome or pattern was reported in 2.3–7.9% of patients in different cohorts, whereas the prevalence of WPW pattern in the general population is estimated to be around 0.25% [42–47]. Since different types of (severe) arrhythmias and even sudden cardiac death can occur in patients with WPW pattern, it seems important that an ECG is conducted at least once in all newly diagnosed non-classic Pompe disease patients [48,49]. In patients with a normal ECG at baseline, repeated ECG could be considered, since WPW pattern may be intermittent and Pompe disease is, despite ERT, a progressive disease [50,51]. It can therefore not be ruled out that glycogen accumulation in cardiac tissue causes conduction abnormalities as the disease progresses.

In case-control studies, severe structural cardiac abnormalities or cardiac dysfunction on TTE or other imaging were not described. In cohort studies, LVH was the most commonly reported TTE/imaging abnormality. Left ventricular hypertrophy or elevated LVMI, was described in 4.6–16.7% of patients, which is comparable to the prevalence in the general population [24,27,29,52]. Left ventricular hypertrophy is mainly caused by long-term pressure and/or volume overload, consequently the prevalence of LVH is higher in a population with high blood pressure [53]. One study reported that all patients with LVH also had other cardiovascular risk factors, including hypertension [29]. The other studies did not report whether patients with LVH also had hypertension, but since mean blood pressure is reported to be increased in non-classic Pompe patients, it is likely that hypertension was prevalent in these cohorts as well [14]. Hypertrophic cardiomyopathy, a hallmark in classic infantile Pompe disease, was described in only three patients in the retrieved studies [25,32]. However, these patients did not carry the common IVS1 mutation and had a (very) early onset of disease, and therefore might be classified as atypical infantile onset patients, rather than non-classic Pompe patients. Only one adult patient, with one mutation with unknown pathogenicity, was reported to have severe dilated cardiomyopathy [33].

The most commonly reported vascular abnormalities in non-classic Pompe patients were (dilicho)ectasias, with a predisposition for the vertebral and/or basilar arteries. One case-control study showed an increased diameter of extra- and intracranial arteries in patients compared to controls matched for age and sex [34]. Importantly, the presence of other cardiovascular risk factors was distributed evenly among patients and controls in this study. In cohort studies, the prevalence of VBD varied between 2% and 72%. Reported estimates of prevalence of VBD in the general population vary from 0.8% to 6.5%, indicating that VBD is more prevalent in Pompe patients [54]. Moreover, (dilicho)ectasias were also described in (very) young Pompe disease patients, with the youngest patient being only 19 years old [55]. Other important vascular abnormalities commonly reported in the included studies were intracranial (anterior and verteobasilar circulation) and aortic aneurysms. Intracranial aneurysms were reported in up to 14% of Pompe patients in different cohort studies, whereas the prevalence of intracranial aneurysms is estimated to be 3.2% in a population without comorbidity [56]. The pathophysiology of these vascular abnormalities is most
likely multifactorial, as both degeneration of smooth muscle cells of arterial walls caused by glycogen accumulation and established cardiovascular risk factors (i.e. hypertension, cigarette smoking, aging) are associated with (dolicho)ectasia and aneurysm formation [54,57-59]. Although asymptomatic in a proportion of patients, the consequences of intracranial (dolicho)ectasia and aneurysms can be serious, with brain infarction, ICH and SAH, and compression of the brainstem being most common [54,60]. Interestingly, ICH and/or SAH as a consequence of intracranial dolichoectasia or aneurysms were only reported in case reports/series and not in any of the cohort studies. Previous studies have shown that ERT can decrease glycogen in arteries and veins, but not completely and not in all patients [6,61,62]. However, as established vascular risk factors also contribute to the pathophysiological mechanisms of arterial widening, monitoring and treatment of these risk factors is particularly important in patients with non-classic Pompe disease.

White matter lesions in a lacunar pattern, characteristic for small vessel disease, were reported in a large proportion of patients in different cohort studies [39,40,63]. However, most of these patients also had other (established) vascular risk factors. Moreover, in a case-control study, Fazekas score and WML volume did not significantly differ between Pompe patients and controls matched for gender, age and number of cerebrovascular risk factors [36]. This suggests that WML in Pompe patients mainly result from other (established) cerebrovascular risk factors. The lacunar pattern of WML reported in non-classic Pompe patients is clearly distinct from the white-matter involvement, which slowly evolves from periventricular to subcortical, described in classic infantile Pompe disease [64]. Severe cognitive decline, as reported in some classic infantile Pompe disease patients, was not reported in non-classic Pompe patients, although one study reported mild cognitive impairment in 52% of patients [40,64,65]. The severity of WML did not correlate with neuropsychological variables in this study, indicating that other factors may play a role in the cognitive impairment in these patients.

As stated previously, arterial stiffness, LVH and WML in Pompe disease patients may also be caused by established cardiovascular risk factors, such as obesity, hypertension, diabetes mellitus and dyslipidemia [53,66-68]. No large study systematically investigated if established cardiovascular risk factors are more prevalent in Pompe disease than in the general population. Studies in Pompe patients reported a large prevalence range for various cardiovascular risk factors, such as for hypertension (22–70%), diabetes (4–20%), and obesity (11–40%). Whether this is different compared to the prevalence of these risk factors in the general population remains to be established. The prevalence of hypertension in adults is estimated to be around 30–45% and increases to over 60% in individuals over the age of 60 years [69]. The global prevalence of diabetes in the general population is estimated to be around 9%, with great variation due to age, regional, income and ethnic differences [70]. Global prevalence of obesity is estimated to be around 13%, increasing up to 26% in high income countries [71]. These large ranges imply that larger case-control studies in Pompe patients are needed before reliable conclusions about these risk factors in comparison to the general population can be drawn. As Pompe disease affects skeletal muscle function, resulting in decreased overall activity level and ability to exercise and decreased resting energy, we hypothesize that these cardiovascular risk factors may be more prevalent in non-classic Pompe patients compared to the general population. This should be objectified in future studies.

It is important to realize that there are large differences between muscle glycogen storage diseases (GSD) in respect to the presence of cardiac abnormalities. In muscle glycogen synthase deficiency (GSD 0b) hypertrophic cardiomyopathy is a key clinical finding [72,73]. In muscle phosphofructokinase (PFKM) deficiency or Tarui disease (GSD VII) cardiomyopathy is rare, but has been described [74]. In phosphoglucomutase 1 deficiency in muscle (GSD XIV) dilated cardiomyopathy and tachycardia have been described in some patients [75–77]. Arrhythmias and cardiomyopathy due to abnormal glycogen storage in the heart are characteristic for glycogenin 1 deficiency (GSD XV) [77–79]. Mutations in the PRKAG2 gene cause glycogen storage cardiomyopathy and conduction system abnormalities [80]. However, not all muscle glycogenoses are associated with cardiac involvement (e.g. muscle phosphorylase deficiency or McArdle disease (GSD V), phosphoglycerate kinase deficiency, lactate dehydrogenase A and B deficiency (GSD XI), aldolase A deficiency (GSD XII), beta-enolase deficiency in muscle (GSD XIII)) [81,82]. Interestingly, arterial ectasia, dilation and aneurysms as reported in Pompe disease, are not characteristic for other muscle glycogenoses [81].

This is the first systemic review that provides an overview of different types of cardiovascular disease described in non-classic Pompe disease. Besides some indications that (intracranial) arterial dolichoectasia and aneurysms may be more common in Pompe disease than in the general population, we found no literature evidence for other clinically significant cardiovascular abnormalities in non-classic Pompe disease patients, in particular in those patients carrying the common IVS1 mutation. Different types of ECG/conduction abnormalities were reported in cohort studies, but a relationship with Pompe disease remains uncertain, and argues for additional (larger) case-control studies. Currently, it seems recommendable to perform an ECG at least once in every newly diagnosed Pompe patient, to investigate for possible arrhythmias or conduction abnormalities. To further investigate the prevalence of cardiovascular disease in non-classic Pompe patients, especially larger case-control studies, that also investigate more established risk factors for cardiovascular disease are indicated. Ideally, patients and controls should be matched not only for age and sex, but also for a variety of established cardiovascular risk factors, in order to draw more robust conclusions about the prevalence of cardiovascular disease in non-classic Pompe disease. Due to the prevalence of the disease, this may require international collaboration.
Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We would like to acknowledge G.B. de Jonge, S. Gunput and M.F.M. Engel of the Medical Library of Erasmus MC for assisting with the literature search.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.nmd.2020.10.009.

References

[1] van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372(9646):1342–53.
[2] Van den Hout HMP, Hop W, Van Diggelen OP, Smeitink JAM, Snijt GPA, Poll-The BTT, et al. The natural course of infantile Pompe’s disease: 20 Original cases compared with 133 cases from the literature. Pediatrics 2003;112(2):332–40.
[3] Van der Beek NAME, Hagemans MLC, Van der Ploeg AT, Reuser AJ, Van Doorn PA. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg 2006;106(2):82–6.
[4] Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab 2017;120(3):163–172.
[5] Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 2019;7(13):284.
[6] McCall AL, Salemi J, Bhanap P, Strickland LM, Elmallah MK. The impact of Pompe disease on smooth muscle: a review. J Smooth Muscle Res 2018;54(0):100–18.
[7] Finsterer J. Dilatative arteriopathy in metabolic myopathies, particularly Pompe’s disease. Acta Neurol Belg 2012;112(1):15–18.
[8] Filosto M, Todeschini A, Cotelli MS, Vielmi V, Rinaldi F, Rota S, et al. Non-muscle involvement in late-onset glycogenosis II. Acta Myol 2013;32(2):91–4.
[9] Kretzschmar HA, Wagner H, Hubner G, Danek A, Witt TN, Mehrain P. Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci 1990;98(2–3):169–83.
[10] Makos MM, McBamb RD, Hart MN, Bennett DR. Alpha-glucosidase deficiency and basilary artery aneurysm: report of a sibship. Ann Neurol 1987;22(5):629–33.
[11] Hobson-Webb LD, Proia AD, Thurtell BL, Banagaria S, Prater SN, Kishnani PS. Autospy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab 2012;106(4):462–9.
[12] Bijvoet AG, Van Hirtum H, Verney M, Van Leenen D, Van Der Ploeg AT, Mooi WJ, et al. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol 1999;189(3):416–24.
[13] Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, et al. Morphological changes in muscle tissue of patients with infantile Pompe’s disease receiving enzyme replacement therapy. Muscle Nerve 2003;27(6):743–51.
[14] Wens SCA, Kuperus E, Mattace-Raso FUS, Kruijshaar ME, Brusse E, Van Montfort KCAGM, et al. Increased aortic stiffness and blood pressure in non-classic Pompe disease. J Inherit Metab Dis 2014;37(3):391–7.
[15] Mattace-Raso FU, van der Cammen TJ, Hofman A, van Pepole NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 2006;113(5):657–63.
[16] van der Ende M, Hartman MH, Hagemeyer Y, Meems LM, de Vries HS, Stolk RP, et al. The lifelines cohort study: prevalence and treatment of cardiovascular disease and risk factors. Int J Cardiol 2017;228:495–500.
[17] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
[18] Morris DA, Blaschke D, Krebs A, Canaan-Kühl S, Pöckinger U, Knobloch G, et al. Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease. Int J Card Imaging 2015;31(5):947–56.
[19] Fayssois A, Nardi O, Amann D, Orlikowski D. Right ventricular function in late-onset Pompe disease. J Clin Monit Comput 2014;28(4):419–21.
[20] Nemes A, Soliman OII, Geleijnse ML, Anwar AM, van der Beek NAME, van Doorn PA, et al. Increased aortic stiffness in glycosgenation type 2 (Pompe’s disease). Int J Cardiol 2007;120(1):138–41.
[21] Boentert M, Florian A, Dräger B, Young P, Uilmaz A. Pattern and prognostic value of cardiac involvement in patients with late-onset Pompe disease: a comprehensive cardiovascular magnetic resonance approach. J Cardiovasc Mag Reson 2016;18(1):91.
[22] Soliman OII, Van Der Beek NAME, Van Doorn PA, Vletter WB, Nemes A, Van Dalen BM, et al. Cardiac involvement in adults with Pompe disease. J Intern Med (GBR) 2008;264(4):333–9.
[23] van der Beek NAME, Soliman OII, van Capelle CI, Geleijnse ML, Vletter WB, Kroos MA, et al. Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities. J Neurol Sci 2008;275(1–2):46–50.
[24] Forsha D, Li J.S., Smith P.B. Cardiovascular abnormalities in late onset Pompe disease and response to enzyme replacement therapy: ncbi.nlm.nih.gov; 2011.
[25] Van Capelle CI, Van Der Meijden JC, Van Den Hout JMP, Jaeken J, Baethmann M, Voit T, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis 2016;11(1):65.
[26] Müller-Felber W, Horvath R, Gempel K. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Elsevier; 2007.
[27] Schüller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet Part C Semin Med Genet 2012;160C(1):80–8.
[28] Forsha D, Li JS, Smith PB, Van Der Ploeg AT, Kishnani P, Pasquali SK. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Gen Med 2011;13(7):625–31.
[29] Herbert M, Cope H, Li JS, Kishnani PS. Severe cardiac involvement is rare in patients with late-onset Pompe disease and the common c.-32-13T>G variant: implications for newborn screening. J Pediatr 2018;198:308–12.
[30] Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscular Disord 2007;17(9–10):696–706.
[31] Alandy-Dy J, Wencel M, Hall K, Simon J, Chen Y, Valenti E, et al. Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease. Ann Transl Med 2019;7(13):276.
Prevalence of obesity among adults: World Health Organisation (WHO); 2020 [Available from: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-obesity-among-adults-bmi=>30-(crude-estimate)-].

Kollberg G, Tulinius M, Gilljam T, Ostman-Smith I, Forsander G, Jotorp P, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 2007;357(15):1507–1514.

Pederson BA, Chen H, Schroeder JM, Shou W, DePaoli-Roach AA, Roach PJ. Abnormal cardiac development in the absence of heart glycogen. Mol Cell Biol 2004;24(16):7179–87.

Musumeci O, Bruno C, Mongini T, Rodolico A, Aguenouz M, Barca E, et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord 2012;22(4):325–30.

Tegtmeier LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, Timal S, et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 2014;370(6):533–42.

Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J, et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet 2012;21(19):4151–61.

Laforté P, Malfatti E, Vissing J. Update on new muscle glycogenosis. Curr Opin Neurol 2017;30(5):449–56.

Moslemi AR, Lindberg C, Nilsson T, Tajsghahi H, Andersson B, Oldfors A. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N Engl J Med 2010;362(13):1203–10.

Hedberg-Oldfors C, Glamazina E, Raygok P, Anderson LJ, Elliott P, Watkinson O, et al. Cardiomyopathy as presenting sign of glycogenin-1 deficiency-report of three cases and review of the literature. J Inherit Metab Dis 2017;40(1):139–49.

Laforté P, Richard P, Said MA, Romero NB, Lacene E, Leroy JP, et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 2006;16(3):178–82.

Kanungo S, Wells K, Tribett T, El-Gharbawy A. Glycogen metabolism and glycogen storage disorders. Ann Transl Med 2018;6(24):474.

Tarnopolsky MA. Myopathies related to glycogen metabolism disorders. Neurotherapeutics 2018;15(4):915–27.

El-Gharbawy AH, Bhat G, Marrillo JE, Thurberg BL, Kannemann C, Mengel KE, et al. Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered. Mol Genet Metab 2011;103(4):362–6.

Sacconi S, Wabbi K, Theodore G, Garcia J, Salvati L, Bouhour F, et al. Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. Neuro muscular Disord 2014;24(7):648–50.

Francesconi M, Auff E. Cardiac arrhythmias and the adult form of type II glycogenosis. N Engl J Med 1982;306(15):937–8.

Miyamoto Y, Etoh Y, Joh R. Adult-onset acid maltase deficiency in siblings. Acta Pathol Jpn 1985;35(6):1533–42.

Braunschweig WE. Fusiform aneurysm of basilar artery and ecstatic internal carotid arteries associated with glycogenosis Type 2 (Pompe’s disease). Neu ro surgery 1987;21(5):748–9.

Matsuioka Y, Senda Y, Hirayama M, Matsui T, Takahashi A. Late-onset acid maltase deficiency associated with intracranial aneurysm. J Neurol 1988;235(6):371–3.

Anneser JMH, Pongratz DE, Podskarbi T, Shin YS, Schoser BGH. Mutations in the α-glucosidase gene (M. Pompe) in a patient with an unusual phenotype. Neurology 2005;64(2):368–70.

Brettschneider J, Sperfeld AD, Ludolph AC, Kassubek J. Intracerebral hemorrhage in a patient with glycogenosis type II (Pompe disease): is there a pathophysiological relationship? Muscle Nerve 2008;38(3):1211–12.

Laforté P, Petitot P, Niccolino M, Orlikowski D, Caillaud C, Pellegrini N, et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 2008;70(22):2063–6.

Renard D, Labauge P. Cerebral microbleeds in Pompe disease. J Neurol Neurosurg Psychiatry 2010;81(11):1217.

Fernández C, Legido A, Jethva R, Marks HG. Correction of a short cardiac PR interval in a 12-year-old girl with late-onset Pompe disease following enzyme replacement therapy. Gen Med 2012;14(8):757–8.

Goebert V, Banz Y, Kaebirich A, Carrel T. Huge aneurysm of the ascending aorta in a patient with adult-type Pompe’s disease: histological findings mimicking fibrillinopathy. Eur J Cardiothorac Surg 2013;43(1):193–5.

Cerón-Rodríguez M, Zamora A, Erdmenger J, Ureha R, Sánchez AC. First case of a patient with late-onset Pompe disease: cardiomyopathy remission with enzyme replacement therapy. Bol Med Hosp Infant Mex 2014;71(1):41–6.

Peric S, Fumic K, Bilic K, Reuser A, Rakovec Stojanovic V. Rupture of the middle cerebral artery aneurysm as a presenting symptom of late-onset Pompe disease in an adult with a novel GAA gene mutation. Acta Neurol Belg 2014;114(2):165–6.

Quenardelle V, Bataillard M, Bazin D, Lannes B, Wolff V, Echazin-Laguna A. Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts. J Neurol 2014;262(2):473–5.

Sandhu D, Rizvi A, Kim J, Reshi R. Diffuse cerebral microhemorrhages in a patient with adult-onset Pompe’s disease: a case report. J Vasc Interv Radiol Neurol 2014;7(5):82–5.

Huded V, Bohra V, Prajapati J, Desouza R, Ramankutty R. Stroke in young – dilative arteriopathy: a clue to late-onset Pompe’s disease? J Stroke Cerebrovasc Dis 2016;25(4):e50–e2.

Zhang B, Zhao Y, Liu J, Li L, Shan J, Zhao D, et al. Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report. Neuropsychiatr Dis Treat 2016;12:713–17.

Malhotra K, Carrington DC. Liebeskind DS. Restrictive arteriopathy in late-onset Pompe disease: case report and review of the literature. J Stroke Cerebrovasc Dis 2017;26(8):e172–e18.

Walczak-Galezewska M, Skrypnik D, Szulinska M, Musialik K, Skrypnik K, Bogdanski P. Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report. Eur Rev Med Pharmacol Sci 2017;21(16):3665–7.

Hossain MA, Miyajima T, Akiiyama K, Eto Y. A case of adult-onset Pompe disease with cerebral stroke and left ventricular hypertrophy. J Stroke Cerebrovasc Dis 2018;27(11):3046–52.

Pappa E, Papadopoulos C, Grimbert P, Laforté P, Bassez G. Renal artery fibromuscular dysplasia in Pompe disease: a case report. Mol Genet Metab Rep 2018;16:64–5.